Resilience to Antibiotic-induced Obesogenic Microbiota: Discovering Mechanism of Microbiota Modulation
Resilience to Antibiotic-induced Obesogenic Microbiota Vertically Transferred to the Neonatal Gut: Discovering Mechanism of Microbiota Modulation
Turku University Hospital
125 participants
May 8, 2024
INTERVENTIONAL
Conditions
Summary
The aim is to study whether the microbiota of children who are exposed to antibiotics at birth could be modified by synbiotic supplement and thereby reduce the risk of obesity, chronic diseases and respiratory tract infections. A total of 125 mother-child pairs will be recruited in this randomized, double-blind, placebo-controlled study. Infants are randomized to receive either a synbiotic supplement or a placebo for 2 months, after which their growth and morbidity will be monitored at the research clinic for 2 years.
Eligibility
Inclusion Criteria1
- Pregnant women (n=125) and their newborn children who receive antibiotic treatment at delivery.
Exclusion Criteria4
- Chorioamnionitis
- Pre-eclampsia and hepatogestosis
- Suspected malformation or serious condition of the foetus and neonates
- Serious infection or other conditions not permitting breast milk feeding
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Bifidobacterium bifidum and human milk oligosaccharides (HMOs)
Maltodextrin
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06974994